PTHS.US Pelthos Therapeutics Inc.
- Market cap
- USD 26.9M
- P/E
- -
- P/B
- 2.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PTHS.US undervalued?
Graham numberThe Graham number of Pelthos Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pelthos Therapeutics Inc. fundamental analysis
No fundamental analysis for Pelthos Therapeutics Inc. yet.
Pelthos Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE…
Full company profilePelthos Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pelthos Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 200K | 0.00 | 0.00 | 0.00 | 0.00 | 16.8M | 55.9M |
| Gross Profit | 200K | - | - | - | 0.00 | 7.43M | 40.0M |
| Operating Income | -1.35M | -839K | -2.32M | -6.86M | -7.57M | -32.4M | -53.5M |
| EBITDA | -659K | -595K | -2.32M | -6.86M | -7.17M | -45.4M | -37.3M |
| Net Income | -661K | -595K | -2.46M | -7.38M | -7.96M | -43.3M | -55.4M |
| EPS | -1.15 | -1.03 | -4.26 | -13 | -14 | -23 | -14 |
| Balance Sheet | |||||||
| Total Assets | - | 0.00 | 55.1K | 96.4K | 1.37M | 130M | 129M |
| Total Liabilities | - | 3.68M | 3.76M | 6.54M | 4.08M | 91.5M | 135M |
| Shareholders' Equity | - | -3.68M | -3.71M | -6.44M | -2.71M | 38.9M | -6.19M |
| Cash & Short-term Investments | - | 0.00 | 55.1K | 96.4K | 513K | 18.0M | 17.7M |
| Total Debt | - | - | 540K | 1.27M | 2.19M | 34.8M | 68.4M |
| Cash Flow | |||||||
| Operating Cash Flow | - | -1.59M | -1.57M | -981K | -5.79M | -22.6M | -34.6M |
| Capital Expenditure | - | 0.00 | 0.00 | 0.00 | 0.00 | 99.0K | 341K |
| Free Cash Flow | - | -1.59M | -1.57M | -981K | -5.79M | -22.7M | -34.9M |
| Ratios | |||||||
| ROE | - | - | - | - | - | -111.4% | - |
| ROA | - | - | -4,464.2% | -7,657.1% | -581.0% | -33.2% | -43.0% |
| Net Profit Margin | -330.4% | - | - | - | - | -257.9% | -99.2% |
| Debt to Equity | - | - | - | - | - | 0.90x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pelthos Therapeutics Inc. dividends
Pelthos Therapeutics Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Jul 2, 2025.
Who owns Pelthos Therapeutics Inc.
- Insiders 48.75%
- Institutions 43.55%
- Public & others 7.71%
- Shares outstanding 3.93M
- Free float 1.47M
Pelthos Therapeutics Inc. company profile
- Company name
- Pelthos Therapeutics Inc.
- Ticker
- PTHS.US
- Exchange
- USA Stocks
- Listed since
- Feb 16, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 92
- Fiscal year end
- December
- Address
- 4020 Stirrup Creek Drive, Durham, NC, United States, 27703
- Phone
- 919 908 2400
- Website
- pelthos.com
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Pelthos Therapeutics Inc. management
3- Mr. Scott M. PleshaCEO, President & Director · born 1965
- Mr. Sai Rangarao M.B.A.Chief Commercial Officer · born 1984
- Mr. John M. Gay CPACFO, Treasurer & Secretary · born 1976